arrow
L

Laura del Hoyo Soriano

institut de recerca sant pau
H指数:13
被引数:770

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Changes in serum β-synuclein precede blood biomarkers of Alzheimer pathology in Down syndrome

血清β-突触蛋白的变化先于唐氏综合征中阿尔茨海默病病理学的血液生物标志物

2026-09-230
OAAI
CSF and plasma tau biomarkers in the Down syndrome–Alzheimer’s disease continuum

脑脊液和血浆tau生物标志物在唐氏综合征–阿尔茨海默病连续谱系中的作用

2026-07-110
OA
The predictive power of neuropsychological measures in MCI: early detection of dementia conversion

轻度认知障碍中神经心理学测量的预测能力:痴呆转化的早期检测

2026-06-010
OA
Peak width of skeletonized mean diffusivity reveals early and multifactorial white matter injury across sporadic and Down syndrome–associated Alzheimer's disease

骨架化平均扩散率峰值宽度揭示散发性和唐氏综合征相关性阿尔茨海默病中早期和多因素白质损伤

2026-05-290
OA
Characterizing circadian rest–activity rhythm patterns across Alzheimer's disease continuum in Down syndrome
2026-04-290
OAAI
Plasma p-tau217 as a biomarker of Alzheimer’s disease pathology in individuals with Down syndrome

血浆p-tau217作为唐氏综合征个体阿尔茨海默病病理的生物标志物

2025-11-100
OAAI
Generational effects in Down syndrome: Enriched environment enhances functionality without reducing Alzheimer's disease risk

唐氏综合征中的代际效应:丰富环境能增强功能,而不会降低阿尔茨海默病风险

2025-10-030
OAAI
Study of brain perfusion in adults with Down syndrome along the Alzheimer's disease continuum

对唐氏综合征成人沿阿尔茨海默病连续谱的脑灌注研究

2025-09-180
OAAI
Discrepancies in assessing intellectual disability levels in adults with Down syndrome: Implications for dementia diagnosis

评估唐氏综合征成人智力障碍水平中的差异:对痴呆诊断的启示

2025-06-170
OAAI
Regional Brain Metabolism across the Alzheimer's Disease Continuum in Down Syndrome
2025-03-140
PRE
Imagine, Discover, Inspire: Proceedings of the 4th International Conference of the Trisomy 21 Research Society

想象,发现,启发: 21三体研究学会第四届国际会议论文集

2025-01-050
OAAI
A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome

1期,随机双盲,安慰剂对照试验,以评估epigallocatechin-3-gallate和认知训练对脆性X综合征成人的安全性和有效性

2020-02-0118
OAAI
Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial
2016-07-01200
PRE